ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.
![Ideaya Biosciences logo](https://files.capedge.com/S-1/0001193125-19-122586/g637842g52d93.jpg)
Company profile
Ticker
IDYA
Exchange
Website
CEO
Yujiro Hata
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
474268251
IDYA stock data
Latest filings (excl ownership)
8-K
Other Events
11 Jul 24
424B5
Prospectus supplement for primary offering
10 Jul 24
424B5
Prospectus supplement for primary offering
9 Jul 24
8-K
Results of Operations and Financial Condition
9 Jul 24
8-K
Other Events
8 Jul 24
8-K
Departure of Directors or Certain Officers
27 Jun 24
8-K
Other Events
3 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
31 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results
7 May 24
Transcripts
Latest ownership filings
4
Jason Throne
27 Jun 24
4
TERRY J ROSEN
31 May 24
4
Susan L. Kelley
31 May 24
4
Malcolm Garret Hampton
31 May 24
4
Jeffrey Stein
31 May 24
4
Scott W Morrison
31 May 24
4
WENDY L YARNO
31 May 24
4
CATHERINE J MACKEY
31 May 24
4
MICHAEL ANTHONY WHITE
31 May 24
144
Notice of proposed sale of securities
29 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm | 109.10 mm |
Cash burn (monthly) | 16.22 mm | (no burn) | 17.01 mm | 13.26 mm | 14.60 mm | 10.93 mm |
Cash used (since last report) | 62.74 mm | n/a | 65.76 mm | 51.29 mm | 56.47 mm | 42.28 mm |
Cash remaining | 46.37 mm | n/a | 43.34 mm | 57.81 mm | 52.63 mm | 66.83 mm |
Runway (months of cash) | 2.9 | n/a | 2.5 | 4.4 | 3.6 | 6.1 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 197 |
Opened positions | 97 |
Closed positions | 10 |
Increased positions | 51 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 3.23 tn |
Total shares | 84.90 mm |
Total puts | 8.50 k |
Total calls | 29.80 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 10.16 mm | $445.61 bn |
BLK Blackrock | 5.97 mm | $261.76 bn |
FHI Federated Hermes Inc - Ordinary Shares | 4.86 mm | $213.08 bn |
Vanguard | 4.16 mm | $182.35 bn |
T. Rowe Price | 4.05 mm | $177.83 mm |
JHG Janus Henderson | 3.81 mm | $167.10 bn |
STT State Street | 3.16 mm | $138.83 bn |
Deerfield Management | 2.63 mm | $115.42 bn |
Adage Capital Partners GP, L.L.C. | 2.47 mm | $108.26 bn |
Biotechnology Value Fund L P | 2.46 mm | $39.06 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 24 | Throne Jason | Common Stock | Option exercise | Acquire M | No | No | 7.01 | 47,060 | 329.89 k | 63,484 |
27 Jun 24 | Throne Jason | Common Stock | Option exercise | Acquire M | No | No | 13.34 | 6,424 | 85.70 k | 16,424 |
27 Jun 24 | Throne Jason | Stock Option Common Stock | Option exercise | Dispose M | No | No | 7.01 | 47,060 | 329.89 k | 1,360 |
27 Jun 24 | Throne Jason | Stock Option Common Stock | Option exercise | Dispose M | No | No | 13.34 | 6,424 | 85.70 k | 41,186 |
31 May 24 | Catherine J Mackey | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Hampton Malcolm Garret | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Rosen Terry J | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
31 May 24 | Kelley Susan L. | Stock Option Common Stock | Grant | Acquire A | No | No | 36.55 | 16,200 | 592.11 k | 16,200 |
News
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $69
12 Jul 24
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61
11 Jul 24
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Jul 24
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
10 Jul 24
Reported Earlier, IDEAYA Prices $263M Public Offering Of 228,572 Common Shares And Pre-Funded Warrants At $35/Share
10 Jul 24
Press releases
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
11 Jul 24
IDEAYA Announces Pricing of Public Offering
9 Jul 24
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
9 Jul 24
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
8 Jul 24
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
5 Jul 24